Veru’s (VERU) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Veru (NASDAQ:VERU) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $5.00 price objective on the stock.

Veru Stock Performance

Shares of VERU opened at $0.73 on Tuesday. The company has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.95. Veru has a fifty-two week low of $0.36 and a fifty-two week high of $1.92. The stock has a market capitalization of $107.18 million, a PE ratio of -1.53 and a beta of -0.47.

Veru (NASDAQ:VERU) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The company had revenue of $3.95 million for the quarter, compared to the consensus estimate of $3.50 million. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. During the same period last year, the business posted ($0.13) EPS. Equities research analysts forecast that Veru will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Veru

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alpine Global Management LLC increased its position in shares of Veru by 21.0% during the first quarter. Alpine Global Management LLC now owns 710,000 shares of the company’s stock worth $497,000 after purchasing an additional 122,999 shares in the last quarter. Ikarian Capital LLC acquired a new position in Veru during the 1st quarter valued at about $663,000. Cetera Advisors LLC purchased a new stake in Veru in the first quarter valued at about $33,000. 180 Wealth Advisors LLC boosted its holdings in Veru by 16.6% in the second quarter. 180 Wealth Advisors LLC now owns 199,100 shares of the company’s stock worth $185,000 after acquiring an additional 28,350 shares in the last quarter. Finally, SeaCrest Wealth Management LLC grew its stake in shares of Veru by 313.8% during the second quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock worth $101,000 after acquiring an additional 91,000 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.